[Pathophysiology and treatment of acute myeloid leukemia].
Naoe
Jomoki
J
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D015316:Genetic Therapy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D011743:Pyrimidines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D014212:Tretinoin / Q000627:therapeutic use; D051941:fms-Like Tyrosine Kinase 3
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D011743:Pyrimidines; D014212:Tretinoin; D000068877:Imatinib Mesylate; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3